Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle

Natera (NTRA) stock witnessed a surge after a jury ruled that the DNA-testing company must pay competitor Ravgen $57 million in a patent lawsuit, significantly lower than the $410 million originally requested. Analyst Kyle Mikson believes this outcome will not hinder Natera’s plans to achieve cash-flow break-even in 2024. Natera intends to appeal the decision, and if it fails, it may have to pay the full $57 million. Meanwhile, Natera stock rose 6.5% to 67, hitting a two-year high. The patent dispute dates back to 2020 when Ravgen claimed Natera’s tests infringed on its patents related to preventing cell lysis.